What is Galecto, Inc.'s current stock price?

Galecto, Inc. (DMRA) currently trades at USD 24.85. Track real-time price changes and historical performance on AllInvestView.

What sector is Galecto, Inc. in?

Galecto, Inc. operates in the Healthcare sector. AllInvestView lets you analyze sector allocation across your entire portfolio.

Galecto, Inc. DMRA Open Galecto, Inc. in new tab

24.85 USD

EPS

-3.98

P/B

-0.22

ROE

-89.51

Beta

1.60

Target Price

45.17 USD

1M 6M YTD 1Y 2Y 5Y Max

Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for Galecto, Inc. (DMRA)

Currency: USD

DCF Assumptions

Revenue growth (YoY) 0.10 Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).

EBITDA margin 0.30 Decimal (e.g., 0.30 = 30%).

Capex (% Revenue) 0.04 Decimal (e.g., 0.04 = 4%).

Tax rate 0.20 Decimal (e.g., 0.20 = 20%).

Terminal growth (g, %) 3% Percent number (e.g., 3 = 3%).

Cost of Equity (%) 10% Percent number (e.g., 10 = 10%).

Cost of Debt (%) 5% Percent number (e.g., 5 = 5%).

DCF Result

Fair Value (DCF)

—

Current Price

—

Upside

—

WACC

—

Terminal PV

—

Σ PV of FCFs

—

Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Galecto, Inc. Analysis (DMRA)

US Healthcare Official Website Stock

Is Galecto, Inc. a good investment? Galecto, Inc. (DMRA) is currently trading at 24.85 USD. Market analysts have a consensus price target of 45.17 USD. This suggests a potential upside from current levels.

Earnings Schedule: Galecto, Inc. is expected to release its next earnings report on Aug. 4, 2026. The market consensus estimate for Forward EPS is -2.11.

Investor FAQ

Does Galecto, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Galecto, Inc.?

Galecto, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 4, 2026. The company currently has a trailing EPS of -3.98.

Company Profile

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Exchange Ticker

NASDAQ DMRA

No dividends available.

Dividends

Historical Split Corporate Actions

Split Date	Split Ratio to 1
Aug. 30, 2024	0.040000

Trades

Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Galecto, Inc. DMRA Open Galecto, Inc. in new tab

Key Metrics

Estimates

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Galecto, Inc. Analysis (DMRA)

Investor FAQ

Company Profile

Dividends

Historical Split Corporate Actions

Explore Premium Features

Under Construction

Community Discussion

Galecto, Inc. DMRA Open Galecto, Inc. in new tab

Key Metrics

Estimates

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Galecto, Inc. Analysis (DMRA)

Investor FAQ

Company Profile

Dividends

Historical Split Corporate Actions

Explore Premium Features

Under Construction

Community Discussion

Notifications